ARTICLE | Clinical News
Eisai's Belviq does not increase MACE in CVOT for weight management drug
August 17, 2018 3:13 AM UTC
Eisai Co. Ltd. (Tokyo:4523) said Belviq lorcaserin met the primary safety endpoint by not increasing the incidence of major adverse cardiovascular events (MACE), comprising CV death, non-fatal myocardial infarction (MI) and non-fatal stroke, in the Phase IIIb/IV CAMELLIA-TIMI 61 cardiovascular outcomes trial (CVOT) of the chronic weight management drug.
Belviq was non-inferior, but not superior, to placebo on the primary efficacy endpoint of reducing the incidence of MACE plus hospitalization due to unstable angina, heart failure or any coronary revascularization...
BCIQ Target Profiles